kynurenine 3-monooxygenase
{{Short description|Enzyme}}
{{infobox enzyme
| Name = kynurenine 3-monooxygenase
| EC_number = 1.14.13.9
| CAS_number = 9029-61-2
| GO_code = 0004502
| image = Kynurenine 3-monooxygenase structure.png
| width =
| caption = Structure of the kynurenine 3-monooxygenase dimer, generated from 4J34.{{cite journal|last1=Amaral|first1=M.|title=Crystal Structure of kynurenine 3-monooxygenase – truncated at position 394 plus HIS tag cleaved|year=2014|doi=10.2210/pdb4j34/pdb}} One monomer is depicted in cartoon format (cyan) and the second monomer is displayed in ribbon format (green). The flexible linker regions (residues 96-104) are colored red. Flavin adenine dinucleotide (FAD) is shown as spheres color-coded according to atom type.
}}
In enzymology, a kynurenine 3-monooxygenase ({{EC number|1.14.13.9}}) is an enzyme that catalyzes the chemical reaction
:Kynurenine + NADPH + H+ + O2 {{eqm}} 3-Hydroxykynurenine + NADP+ + H2O
Kynurenine 3-monooxygenase is the expression product of the KMO (gene). The systematic name of this enzyme class is {{sc|L}}-kynurenine, NADPH:oxygen oxidoreductase (3-hydroxylating). Other names in common use include kynurenine 3-hydroxylase, kynurenine hydroxylase, and {{sc|L}}-kynurenine-3-hydroxylase. It participates in tryptophan metabolism through the kynurenine catabolic pathway. This enzyme belongs to the family of oxidoreductases, to be specific, those acting on paired donors, with O2 as the oxidant. Kynurenine 3-monooxygenase catalyzes the insertion of molecular oxygen into the aromatic ring of kynurenine to produce 3-hydroxy-{{sc|L}}-kynurenine.{{cite book|last1=Filippini|first1=Graziella Allegri|last2=Costa|first2=Carlo V. L.|last3=Bertazzo|first3=Antonella|last4=International Meeting on Tryptophan Research|title=Recent advances in tryptophan research : tryptophan and serotonin pathways|series=Advances in Experimental Medicine and Biology|volume=398|date=1998|doi=10.1007/978-1-4613-0381-7|isbn=978-1-4613-8026-9|s2cid=38080353}} It employs one cofactor, FAD. Kynurenine 3-monooxygenase serves as an important branch point in the kynurenine pathway and, as a result, is an attractive drug target for immunological, neurodegenerative, and neuroinflammatory diseases.{{cite journal|last1=Smith|first1=Jason R.|last2=Jamie|first2=Joanne F.|last3=Guillemin|first3=Gilles J.|author3-link=Gilles J. Guillemin|title=Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors|journal=Drug Discovery Today|volume=21|issue=2|date=February 2016|pages=315–324|issn=1359-6446|doi=10.1016/j.drudis.2015.11.001|pmid=26589832}} Currently, most research on the kynurenine 3-monooxygenase enzyme has been focused primarily on rat models{{cite journal|last1=Horn|first1=U.|last2=Ullrich|first2=V.|last3=Staudinger|first3=H.J|title=Purification and characterization of {{sc|L}}-kynurenine 3-hydroxylase (EC 1.14.1.2.) from rat liver|journal=Hoppe-Seyler's Z. Physiol. Chem.|year=1971|volume=352|issue=6|pages=837–842|doi=10.1515/bchm2.1971.352.1.837|pmid=5087636}} and in yeast,{{cite journal|last1=Amaral|first1=M|last2=Levy|first2=C|last3=Heyes|first3=DJ|last4=Lafite|first4=P|last5=Outeiro|first5=TF|last6=Giorgini|first6=F|last7=Leys|first7=D|last8=Scrutton|first8=NS|title=Structural basis of kynurenine 3-monooxygenase inhibition|journal=Nature|year=2013|volume=496|issue=7445|pages=382–385|doi=10.1038/nature12039|pmid=23575632|pmc=3736096|bibcode=2013Natur.496..382A}} both of which have been demonstrated to have high sequence homology with the human kynurenine 3-monooxygenase protein. Studies have shown the beneficial effects of enzyme inhibition in these eukaryotic kynurenine 3-monooxygenase active sites, thus making this enzyme an attractive target for human drug design.
Structure
Kynurenine 3-monooxygenase is a dimer containing asymmetric subunits and has one FAD-binding domain as its prosthetic group. Kynurenine 3-monooxygenase contains a linker region involved in substrate binding following a second strand of an antiparallel β-sheet, a six-stranded antiparallel β-sheet domain, and an α-helix at the carboxy-terminal. The hydrophobic C-terminus acts as the mitochondrial anchoring domain and participates in enzymatic activity.{{cite journal|vauthors=Hirai KH|display-authors=etal|title=Dual role of the carboxyl-terminal region of pig liver {{sc|L}}-kynurenine 3-monooxygenase: mitochondrial-targeting signal and enzymatic activity|journal=J. Biochem.|volume=148|issue=6|year=2010|pages=639–650|doi=10.1093/jb/mvq099|pmid=20802227}}
Active site
While no scientific literature reports a crystal image of a kynurenine 3-monooxygenase complex with {{sc|L}}-kynurenine, structural studies of the enzyme in yeast co-crystallized with UPF 648 reveal how the FAD cofactor and substrate are bound in the active site. Chemical similarities between UPF 648 and {{sc|L}}-kynurenine suggest that the substrate binds adjacent to the Re-face of the flavoprotein. A loop containing the residues Pro321–Gln325 is believed to be the oxygen-binding site above the re-side of the FAD prosthetic group.
Each monomer contains a conserved hydrophobic pocket (residues Leu221, Met230, Ile232, Leu234, Phe246, Pro321, Phe322) positioned around the substrate's aromatic benzene moiety. A conserved Gln325 polar residue is also involved in hydrogen bonding on the {{sc|L}}-kynurenine carbonyl group, as well as on the hydrogen on the FAD N3 atom. Arg83 and Tyr97 also form polar contacts with the carboxylate in the amino acid moiety on the substrate.{{cite journal|vauthors=Mole D |display-authors=etal |title=Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis|journal=Nature Medicine|volume=22|pages=202–209|year=2016|issue=2 |doi=10.1038/nm.4020|pmid=26752518|pmc=4871268}}
Mechanism
Kynurenine-3-monooxygenase catalyzes the hydroxylation of {{sc|L}}-kynurenine to 3-hydroxy-{{sc|L}}-kynurenine with concomitant interconversion of NADPH to NADP+. The reaction mechanism is not entirely known, but is believed to follow mechanisms related to the flavin-dependent monooxygenases.{{cite journal|author=Breton, J. |display-authors=etal |title=Functional characterization and mechanism of action of recombinant human kynurenine 3-hydroxylase|journal=Eur. J. Biochem.|volume=267|year=2000|issue=4 |pages=1092–1099|pmid= 10672018|doi=10.1046/j.1432-1327.2000.01104.x|doi-access=free}} After {{sc|L}}-kynurenine binds, NADPH reduces FAD and leaves as NADP+. Oxygen then binds and creates an {{sc|L}}-kynurenine-FAD-hydroperoxide intermediate.{{cite journal |author=Crozier-Reabe, KR |display-authors=etal|title=Kynurenine 3-monooxygenase from Pseudomonas fluorescens: substrate-like inhibitors both stimulate flavin reduction and stabilize the flavin-peroxo intermediate yet result in the production of hydrogen peroxide|journal=Biochemistry|volume=47|year=2008|issue=47|pages=12420–12433|pmid=18954092|doi=10.1021/bi8010434}} This intermediate is the electrophilic source for the hydroxylation reaction, yielding a primary ketimine form of the product and the C4a-hydroxy-FAD.{{cite journal|vauthors=Entsch B|display-authors=etal|year=1976|title=Flavin-oxygen derivatives involved in the hydroxylation of p-hydroxybenzoate hydroxylase|journal=J. Biol. Chem.|volume=251|issue=9|pages=2550–2563|doi=10.1016/S0021-9258(17)33523-8|pmid=816794|doi-access=free}} Tautomerization yields 3-hydroxy-{{sc|L}}-kynurenine in complex with the enzyme (E Fl HOH-P). Dissociation of 3-hydroxy-{{sc|L}}-kynurenine and H2O leads to the free enzyme (E Flox).
Biological function
Kynurenine 3-monooxygenase catalyzes the conversion of {{sc|L}}-kynurenine to 3-hydroxy-{{sc|L}}-kynurenine, an important bioactive metabolite in the kynurenine pathway. The kynurenine pathway is responsible for over 95% of tryptophan oxidative degradation.{{cite journal |vauthors=Thevandavakkam MA |display-authors=etal|year=2010|title=Targeting kynurenine 3-monooxygenase (KMO). Implications for therapy in Huntington's disease|journal=CNS Neurol. Disord. Drug Targets|volume=9|issue=6|pages=791–800|pmid=20942784|doi=10.2174/187152710793237430}} {{sc|L}}-Kynurenine is an important branch point of this metabolic pathway, being converted into the neurotoxin 3-hydroxy-{{sc|L}}-kynurenine via kynurenine 3-monooxygenase, the neuroprotectant kynurenic acid through kynurenine amino transferases, or anthranilic acid by kynureninase.{{cite journal|vauthors=Giorgini F, Huang SY, Sathyasaikumar KV|display-authors=etal|title=Targeted Deletion of Kynurenine 3-Monooxygenase in Mice: A New Tool for Studying Kynurenine Pathway Metabolism in Periphery and Brain|journal=The Journal of Biological Chemistry|year=2013|volume=288|issue=51|pages=36554–36566|doi=10.1074/jbc.M113.503813|pmid=24189070|pmc=3868768|doi-access=free}}
Kynurenine 3-monooxygenase regulates the downstream production of quinolinic acid, which can generate reactive free radicals{{cite journal|last1=Rios|first1=C.|last2=Santamaria|first2=A.|year=1991|title=Quinolinic acid is a potent lipid peroxidant in rat brain homogenates|journal=Neurochem. Res.|volume=16|issue=10|pages=1139–1143|pmid=1686636|doi=10.1007/bf00966592|s2cid=28669340}} and activates the NMDA subtype of glutamate receptors, producing excitotoxic lesions in the central nervous system of mammals.{{cite journal|last1=Stone|first1=T. W.|last2=Perkins|first2=M. N.|year=1981|title=Quinolinic acid: A potent endogenous excitant at amino acid receptors in CNS|journal=Eur. J. Pharmacol.|volume=72|issue=4|pages=411–412|pmid=6268428|doi=10.1016/0014-2999(81)90587-2}}{{cite journal|last1=Schwarcz|first1=R.|last2=Bruno|first2=J. P.|last3=Muchowski|first3=P. J.|last4=Wu|first4=H. Q.|year=2012|title=Kynurenines in the mammalian brain. When physiology meets pathology|journal=Nat. Rev. Neurosci.|volume=13|issue=7|pages=465–477|pmid=22678511|doi=10.1038/nrn3257|pmc=3681811}} Quinolinic acid is also the bioprecursor of NAD+.
Inhibition of kynurenine 3-monooxygenase leads to an increase of kynurenic acid in the kynurenine pathway. This metabolite functions as an antagonist of the α7 nicotinic acetylcholine receptor and as an antagonist at the glycine site of the NMDA receptor.{{cite journal|last1=Hilmas|first1=C.|last2=Pereira|first2=E. F.|last3=Alkondon|first3=M.|last4=Rassoulpour|first4=A.|last5=Schwarcz|first5=R.|last6=Albuquerque|first6=E. X.|year=2001|title=The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression:Physiopathological implications|journal=J. Neurosci.|volume=21|issue=19|pages=7463–7473|doi=10.1523/JNEUROSCI.21-19-07463.2001|pmid=11567036|doi-access=free|pmc=6762893}} As a result, regulation at the kynurenine 3-monooxygenase enzyme determines the neurotoxic and neuroprotective potential of the kynurenine pathway.
Disease relevance
Kynurenine 3-monooxygenase is an attractive drug target for several neurodegenerative and neuroinflammatory diseases, especially Huntington's, Alzheimer's, and Parkinson's disease. Administration of potent enzyme inhibitors has demonstrated promising pharmacological results. Specifically, genetic elimination of the kynurenine 3-monooxygenase enzyme has been shown to suppress toxicity of the huntingtin protein in yeast{{cite journal|last1=Giorgini|first1=F.|last2=Guidetti|first2=P.|last3=Nguyen|first3=Q.|last4=Bennett|first4=S. C.|last5=Muchowski|first5=P. J.|year=2005|title=A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease|journal=Nat. Genet.|volume=37|issue=5|pages=526–531|pmid=15806102|doi=10.1038/ng1542|pmc=1449881}} and Drosophila{{cite journal|last1=Campesan|first1=S.|last2=Green|first2=E. W.|last3=Breda|first3=C.|last4=Sathyasaikumar|first4=K. V.|last5=Muchowski|first5=P. J.|last6=Schwarcz|first6=R.|last7=Kyriacou|first7=C. P.|last8=Giorgini|first8=F|year=2011|title=The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease|journal=Curr. Biol.|volume=21|issue=11|pages=961–966|pmid= 21636279|doi=10.1016/j.cub.2011.04.028|pmc=3929356}} models of Huntington's disease.
Kynurenine 3-monooxygenase deficiency, which can be caused by genetic polymorphisms, cytokines, or both,{{cite journal|last1=Müller|first1=N|last2=Myint|first2=AM|last3=Schwarz|first3=MJ|year=2010|title=Inflammatory Biomarkers and Depression|journal=Neurotox. Res.|volume=19|issue=2|pages=308–318|doi=10.1007/s12640-010-9210-2|pmid=20658274|s2cid=3225744}} leads to an accumulation of kynurenine and to a shift within the tryptophan metabolic pathway towards kynurenic acid and anthranilic acid. Recent research suggests that hyperphysiologic concentrations of kynurenine in kynurenine 3-monooxygenase-deficient patients results in a shift towards kynurenic acid production, believed to be related to cognitive deficits in predictive pursuit and visuospatial working memory.{{cite journal|vauthors=Wonodi I, Colin-Stine O, Sathyasaikumar KV|display-authors=etal|title=Downregulated Kynurenine 3-Monooxygenase Gene Expression and Enzyme Activity in Schizophrenia and Genetic Association With Schizophrenia Endophenotypes|journal=Arch Gen Psychiatry|year=2011|volume=68|issue=7|pages=665–674|pmid= 21727251|doi=10.1001/archgenpsychiatry.2011.71|pmc=3855543}} Kynurenine-3-monooxygenase deficiency is associated with disorders of the brain (e.g. schizophrenia, tic disorders) and of the liver.{{cite journal|vauthors=Holtze M, Saetre P, Engberg G|display-authors=etal|title=Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls|journal=J Psychiatry Neurosci|year=2012|volume=37|issue=1|pages=53–57|doi=10.1503/jpn.100175|pmid= 21693093|pmc=3244499}}{{cite journal|first1=Brian M.|last1=Campbell|first2=Erik|last2=Charych|first3=Anna W.|last3=Lee|first4=Thomas|last4=Möller|title=Kynurenines in CNS disease: regulation byinflammatory cytokines|journal=Frontiers in Neuroscience |year=2014|volume=8|issue=12|page=12|doi=10.3389/fnins.2014.00012|pmid=24567701|pmc=3915289|doi-access=free}}{{cite journal|last1=Hoekstra|first1=PJ|last2=Anderson|first2=GM|last3=Troost|first3=PW|title=Plasma kynurenine and related measures in tic disorder patients|journal=Eur Child Adolesc Psychiatry|year=2007|volume=16|issue=Suppl 1|pages=71–77|doi=10.1007/s00787-007-1009-1|pmid= 17665285|s2cid=39150343}}{{cite journal|vauthors=Buness A, Roth A, Herrmann A, Schmitz O, Kamp H|display-authors=etal|year=2014|title=Identification of Metabolites, Clinical Chemistry Markers and Transcripts Associated with Hepatotoxicity|journal=PLOS ONE|volume=9|issue=5|doi=10.1371/journal.pone.0097249|pages=e97249|pmid=24836604|pmc=4023975|bibcode=2014PLoSO...997249B|doi-access=free}}{{cite journal|first1=Hirata|last1=Yukiko|first2=Kawachi|last2=Takashi|first3=Sugimura|last3=Takashi|title=Fatty liver induced by injection of {{sc|L}}-tryptophan|journal=Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism|volume=144|issue=2|date=2 October 1967|pages=233–241|doi=10.1016/0005-2760(67)90153-1|pmid=4168935}}
References
{{reflist}}
{{refbegin}}
- {{cite journal |vauthors=Foucher AL, McIntosh A, Douce G, Wastling J, Tait A, Turner CM | date = 2006 | title = A proteomic analysis of arsenical drug resistance in Trypanosoma brucei | journal = Proteomics | volume = 6 | pages = 2726–2732 | pmid = 16526094 | doi = 10.1002/pmic.200500419 | issue = 9 | s2cid = 24074942 }}
- {{cite journal |vauthors=Okamoto H, Hayaishi O | date = 1967 | title = Flavin adenine dinucleotide requirement for kynurenine hydroxylase of rat liver mitochondria | journal = Biochem. Biophys. Res. Commun. | volume = 29 | pages = 394–399 | pmid = 6076241 | doi = 10.1016/0006-291X(67)90469-X | issue = 3 }}
- {{cite journal |vauthors=Saito Y, Hayaishi O, Rothberg S | date = 1957 | title = Studies on oxygenases; enzymatic formation of 3-hydroxy-{{sc|L}}-kynurenine from {{sc|L}}-kynurenine | journal = J. Biol. Chem. | volume = 229 | pages = 921–934 | pmid = 13502353 | issue = 2 | doi = 10.1016/S0021-9258(19)63696-3 | doi-access = free }}
{{refend}}
{{Dioxygenases}}
{{Enzymes}}
{{Portal bar|Biology|border=no}}